DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai, based in Woodcliff Lake, NJ, USA, for the production of sterile products.

The agreement covers the production of eribulin mesylate as well as other developmental drugs.

DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. L

No financial details were disclosed.